To include your compound in the COVID-19 Resource Center, submit it here.

Albuvirtide: Interim Phase III data

Interim data from 96 evaluable HIV-infected patients who failed first-line antiretroviral therapy (ART) in the modified intent-to-treat (mITT)

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE